Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | Next revisionBoth sides next revision | ||
| content:neonatal_seizures [2020/02/23 14:42] – [Management] icna | content:neonatal_seizures [2020/02/23 14:46] – [Management] icna | ||
|---|---|---|---|
| Line 182: | Line 182: | ||
| * extremely limited evidence on the effect of phenobarbital on long-term neonatal neurodevelopment | * extremely limited evidence on the effect of phenobarbital on long-term neonatal neurodevelopment | ||
| * U.S. Food and Drug Administration (FDA) has never approved phenobarbital for use in any patient population[(: | * U.S. Food and Drug Administration (FDA) has never approved phenobarbital for use in any patient population[(: | ||
| + | * animal studies have raised concerns that neonatal phenobarbital exposure induces neuronal apoptosis, disruption of synaptic development in the striatum, and other behavioral deficits[(: | ||
| * **Levetiracetam** | * **Levetiracetam** | ||
| * effective as second-line treatments for neonatal seizures that are unresponsive to phenobarbital | * effective as second-line treatments for neonatal seizures that are unresponsive to phenobarbital | ||